Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
REGULATORY
Maintain Funding for COVID Pill beyond April: Academic Societies to Govt
Three Japanese academic associations on February 8 submitted a request to Health Minister Keizo Takemi, urging the government to continue public funding for oral COVID-19 medicines beyond April to help keep down patients’ out-of-pocket payments. In Japan, three oral therapies…
To read the full story
Related Article
- Japan to End Public Aid for COVID Drugs at March-End
February 21, 2024
- Academic Societies to Urge Govt to Continue Funding for COVID Pills beyond April
February 5, 2024
- Transitional Pneumovax Program for Age 70 and Up Set to End in March
December 4, 2023
- Keep Public Funding for COVID Drugs to Get through This Winter: Academic Societies
May 25, 2023
- Japan to Offer COVID Drugs for Free until September-End
March 13, 2023
REGULATORY
- PMDA Announces Guidance on “Competing Products” in Regulatory Review
April 8, 2025
- MHLW Now Soliciting Bids for FY2025 Budget Projects to Fight Drug Lag/Loss
April 8, 2025
- Ishiba, Trump Agree to Appoint Ministers for Tariffs Talks
April 8, 2025
- Public-Private Council Will Meet This Summer: Japan PM
April 8, 2025
- Ishin Prods Govt to End Fee Incentives for Generic Use, Minister Says Topic Up for Chuikyo Discussions
April 7, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…